Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Zhang, Meini
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)	Recruiting	2/3	132	RoW	B001, Placebo	Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd	Neuromyelitis Optica Spectrum Disorders	10/27	02/29
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders	Recruiting	2	162	RoW	BAT4406F Injection, BAT4406F Placebos	Bio-Thera Solutions	Optic Neuromyelitis Spectrum Disease	05/25	05/26
NCT04711148: A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis	Active, not recruiting	2	160	Europe, US, RoW	placebo, orelabrutinib	Beijing InnoCare Pharma Tech Co., Ltd.	Relapsing Remitting Multiple Sclerosis	02/26	03/26
NCT05145361: Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)	Recruiting	1	45	RoW	B001 injection, Placebo	Shanghai Pharmaceuticals Holding Co., Ltd	NMO Spectrum Disorder	12/25	12/25